Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Metolazone · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Metolazone Tablets 10 mg |
| 2 | ACTIVE_COMPARATOR | Zaroloxyn® Tablets 10 mg |
| Name | Type | Description |
|---|---|---|
| Metolazone Tablets 10 mg | DRUG | 10mg, single dose fasting |
| Zaroloxyn® Tablets 10 mg | DRUG | 10mg, single dose fasting |
| Metolazone Tablets 5 mg | DRUG | 2x5mg, single dose fasting |
| Zaroloxyn® Tablets 5 mg | DRUG | 2x5mg, single dose fasting |
| Metolazone Tablets 2.5 mg | DRUG | 4x2.5mg, single dose fasting |
| Zaroloxyn® Tablets 2.5 mg | DRUG | 4x2.5mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older 2. Sex: Male and/or non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum b-human chorionic gonadotropin (β-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening pr...
Metolazone is a small molecule drug being developed by Viatris Inc. for use in healthy volunteers. It is currently in Phase 1 clinical development, with three completed trials studying the drug in healthy individuals. The drug is not yet approved and remains investigational.
Metolazone is developed by Viatris Inc., a company traded on the stock exchange under the ticker VTRS. The drug is currently in Phase 1 clinical development, with all three completed trials conducted in healthy volunteers in the United States.
Metolazone is in Phase 1 clinical development. All three clinical trials for the drug have been completed, with a total enrollment of 160 healthy volunteers. The drug is investigational and has not been approved by regulatory authorities.
Metolazone has three completed Phase 1 clinical trials: NCT00649051, NCT00649181, and NCT00650195. These fasting studies compared Metolazone tablets at doses of 2.5 mg, 5 mg, and 10 mg against Zaroloxyn tablets in healthy volunteers in the United States.
Metolazone is being studied in clinical trials as a generic version of Zaroloxyn. The three Phase 1 trials compare Metolazone tablets at 2.5 mg, 5 mg, and 10 mg doses to Zaroloxyn tablets at the same strengths in healthy volunteers.